Journal
QUALITY OF LIFE RESEARCH
Volume 23, Issue 1, Pages 103-117Publisher
SPRINGER
DOI: 10.1007/s11136-013-0442-5
Keywords
Endometriosis; Health-related quality of life; SF-36; Psychometric validation
Categories
Funding
- Bayer Pharma AG
- Bayer HealthCare AG
Ask authors/readers for more resources
Endometriosis presents with significant pain as the most common symptom. Generic health measures can allow comparisons across diseases or populations. However, the Medical Outcomes Study Short Form 36 (SF-36) has not been validated for this disease. The goal of this study was to validate the SF-36 (version 2) for endometriosis. Using data from two clinical trials (N = 252 and 198) of treatment for endometriosis, a full complement of psychometric analyses was performed. Additional instruments included a pain visual analog scale (VAS); a physician-completed questionnaire based on patient interview (modified Biberoglu and Behrman-B & B); clinical global impression of change (CGI-C); and patient satisfaction with treatment. Bodily pain (BP) and the Physical Component Summary Score (PCS) were correlated with the pain VAS at baseline and over time and the B&B at baseline and end of study. In addition, those who had the greatest change in BP and PCS also reported the greatest change on CGI-C and patient satisfaction with treatment. Other subscales showed smaller, but significant, correlations with change in the pain VAS, CGI-C, and patient satisfaction with treatment. The SF-36-particularly BP and the PCS-appears to be a valid and responsive measure for endometriosis and its treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available